SCHEMBL7183312

SCHEMBL7183312

Cc1cc(C)c(C(=O)C(OCCOP=O)c2ccccc2)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.38
GAA P10253 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 4/20 0.37
KEAP1 Q14145 3/20 0.36
NFE2L2 Q16236 3/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
PPARA Q07869 2/20 0.36
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7181535 0.90 L3MBTL1 (0.40) LMNAGAAHTTALDH1A1PPARA
SCHEMBL7735689 0.89 LMNA (0.35) LMNAGAAHTTALDH1A1KEAP1
SCHEMBL19514184 0.82 LMNA (0.40) LMNAGAAHTTALDH1A1SLC6A2
SCHEMBL7177121 0.82 TRPM4 (0.38) LMNAGAAALDH1A1PPARACYP3A4
SCHEMBL9874802 0.81 LMNA (0.42) LMNAGAAHTTALDH1A1KEAP1
SCHEMBL7181341 0.80 CA12 (0.42) LMNAALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL19185660 0.80 THRB (0.45) LMNAGAAHTTALDH1A1SLC6A2
SCHEMBL7181149 0.80 HPGD (0.39) GAAALDH1A1KEAP1NFE2L2CYP3A4
SCHEMBL19514211 0.79 LMNA (0.33) LMNAGAAHTTALDH1A1SLC6A2
SCHEMBL20997310 0.78 LMNA (0.39) LMNAGAAHTTALDH1A1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885GAA 4753/4885HTT 2802/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885GAA 4793/4885HTT 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.